Objectives: We compared the effectiveness of cefazolin versus cloxacillin in the treatment of MSSA bacteraemia in terms of mortality and relapse.
Introduction
Staphylococcus aureus bacteraemia (SAB) is a leading bloodstream infection, with 10% -30% mortality.
1 -4 Standard treatment for MSSA bacteraemia includes antistaphylococcal penicillins such as cloxacillin. 5, 6 Cefazolin, a first-generation cephalosporin available in North America but not in the UK, is also frequently used for MSSA due to its tolerability and convenient dosing. In current guidelines, cefazolin is second-line treatment for MSSA bacteraemia. 5 -7 Type A b-lactamase production in large-inoculum S. aureus infection can inactivate cefazolin, which may theoretically contribute to cefazolin treatment failure. 8 -11 However, the comparative clinical effectiveness of cefazolin and antistaphylococcal penicillins in SAB is unclear. To our knowledge, only three relatively small cohort studies have compared cefazolin with antistaphylococcal penicillins, and showed no statistical difference in clinical outcomes such as mortality and treatment failure. 12 -14 However, statistical insignificance does not translate to no clinical difference. In the three studies, wide CIs that cross 1 do not support the conclusion of no clinical difference. 12 -14 In these studies, small sample size and low event rate contributed to the wide CI; sample size was 41-72 in the cefazolin group. 12 -14 # The Author 2015. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com
We compared the effectiveness of cloxacillin with that of cefazolin as the definitive antibiotic therapy for MSSA bacteraemia in terms of mortality and relapse.
Methods

Study design
We conducted a retrospective cohort study at six acute-care academic and community hospitals in the Greater Toronto Area, which accounted for a total of 2968 acute-care beds and 145 000 annual patient admissions. Consecutive patients were recruited from 1 April 2007 to 31 March 2010. Research Ethics Board approval was obtained from each institution. Patient consent for data collection was not obtained due to the retrospective cohort nature of the study. Waiver of consent was approved by all site Research Ethics Boards.
Patients were included if they had at least one positive blood culture for S. aureus. Identification of S. aureus and antimicrobial susceptibility testing of blood cultures were based on CLSI guidelines. 15 Patients under the age of 18 were excluded. Additionally, patients were excluded if any of the following occurred within 3 days of blood culture: death; left against medical advice; or deemed palliative. The threshold of 3 days was chosen because .90% of blood cultures returned antibiotic susceptibility results within 3 days. Thus, antibiotic therapy after 3 days was considered to be not empirical, but definitive.
Only patients with MSSA bacteraemia treated with cefazolin or cloxacillin as the predominant antibiotic during their antibiotic course were included in the analysis. The predominant antibiotic was defined as the only antibiotic used for .3 days and for the majority (.50%) of the time during the antibiotic course.
Data collection
Data were obtained from patients' electronic and paper medical records at each site and entered into a standardized case report form. Collected data included patient demographics, comorbidities, microbiological data, antibiotic treatment, investigations and clinical outcomes.
Patient characteristics and SAB clinical characteristics
Nosocomial, healthcare-associated and community-acquired infections were based on standard definitions. 16 Patients were assumed to have community-acquired infection unless proven otherwise.
High-and intermediate-risk cardiac conditions were defined according to American Heart Association guidelines for infective endocarditis. 17 Immune suppression was defined as high-dose corticosteroid (.10 mg of prednisone or equivalent), HIV/AIDS, chemotherapy within the last 6 weeks, neutropenia within 72 h of bacteraemia or transplantation requiring immunosuppressive therapy.
Renal insufficiency was defined as serum creatinine .177 mmol/L within 24 h of bacteraemia. Early infectious foci were defined as documented foci preceding or within 3 days of blood culture collection, whereas late infectious foci were defined as any documented foci after 3 days following blood culture collection. Endocarditis was adjudicated using the modified Duke criteria. 
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Antibiotic therapy
For MSSA, appropriate antibiotics included intravenous antistaphylococcal b-lactams, quinupristin/dalfopristin, daptomycin and vancomycin. Duration of antibiotic treatment was calculated from the start of appropriate antibiotic closest to blood culture collection date. For patients discharged alive, the planned treatment stop date was considered as the last day of appropriate antibiotics.
Outcomes
The primary outcome was mortality within 90 days. All patient outcomes were followed until death in hospital or 90 days, whichever came first.
Patients were lost to follow-up if they did not return to hospital for follow-up or readmission. The secondary outcome was relapse, which was defined as any positive culture for S. aureus isolated from a suspected infectious focus after discontinuation of an antibiotic course and within 90 days of follow-up. Isolates were considered as relapses unless the susceptibility pattern differed from that of the original SAB.
Statistical analysis
Comparisons between cefazolin and cloxacillin groups were done with the Wilcoxon rank sum test for non-normally distributed continuous variables and Fisher's exact test for categorical variables.
A Cox proportional-hazards regression model was used to characterize 90 day mortality. In the univariate analysis, patient baseline characteristics and SAB clinical characteristics with the exception of variables beyond 3 days were considered potential predictors. All predictors with P,0.2 on univariate analysis were included in the final multivariable Cox proportionalhazards regression model along with predominant antibiotic choice.
The propensity score for predominant antibiotic choice was estimated using a logistic regression using all baseline patient characteristics as listed in Table 3 . Cefazolin patients were matched in a 1 : 1 ratio to cloxacillin patients using nearest neighbour matching with a specified calliper width of 0.25 times the standard deviation of the logit of propensity scores.
All reported CIs were two-sided 95% intervals and all tests were twosided with a P,0.05 significance level. All analyses were done with R version 3.1.1 (R Foundation for Statistical Computing, Vienna, Austria).
Results
Of 969 patients with at least one positive S. aureus blood culture, 354 were eligible for the study, which included 249 (70%) patients who received cloxacillin and 105 (30%) patients who received cefazolin as the predominant antibiotic (Figure 1 ). Antibiotic therapy and survival for excluded patients are listed in Table S1 (available as Supplementary data at JAC Online) and Figure S1 . Antibiotic assignment and mortality rate were similar between calendar years (Table S2) .
Patient baseline and SAB clinical characteristics
Baseline patient characteristics and SAB clinical characteristics of the cefazolin and cloxacillin groups are listed in Table 1 . Among the 354 SAB cases, there was no resistance to cefazolin or cloxacillin based on MIC cut points in the CLSI guidelines. 15 
Antibiotic treatment
Of all patients, 318 (90%) received appropriate antibiotics within 2 days of blood culture: 93/105 (89%) cefazolin patients and 225/249 (90%) cloxacillin patients (P¼0.7004).
All patients, including those who died while receiving antibiotics, received a median of 18 days (IQR 13 -32 days) of 16 Healthcare-associated infection was defined as a positive blood culture within 2 days of hospital admission from a patient who fulfilled any of the following criteria: (i) attended hospital or haemodialysis clinic or intravenous chemotherapy clinic within 30 days before the infection; (ii) received intravenous therapy at home; (iii) received wound care or nursing care through a healthcare agency; (iv) performed self-administered intravenous medical therapy within 30 days of infection; (v) hospitalized in an acute-care facility within 90 days of infection; or (vi) resided in a long-term care or nursing home. Nosocomial infection was defined as a positive blood culture from a patient admitted to hospital for ≥2 days. Community-acquired infection was defined as a positive blood culture within 2 days of hospital admission from a patient who did not satisfy the criteria for healthcare-associated infection. Other foci included intra-abdominal infection, biliary tract infection, CNS infection, endovascular infection, mycotic aneurysm, cardiac device infection and any other infectious foci that did not belong in the infectious foci categories. appropriate antibiotics. Cefazolin patients received a median of 17 days (IQR 13 -31 days) and cloxacillin patients received a median of 19 days (IQR 13 -34 days) of appropriate antibiotics (P ¼ 0.4146). Cefazolin accounted for a median of 86% (IQR 75% -94%) of total appropriate antibiotic days in cefazolin patients, whereas cloxacillin accounted for a median of 88% (IQR 78% -94%) of total appropriate antibiotic days in cloxacillin patients (P ¼ 0.1957).
The standard cloxacillin dosage was 8 -12 g daily. The median daily dose was 12 g (IQR 8 -12 g) for cloxacillin patients. For 19 obese cloxacillin patients (recorded weight .90 kg) the median daily dose was 12 g (range 8 -18 g). The standard cefazolin dosage was 3 g daily. The median dose was 3 g (IQR 3 -3 g) for cefazolin patients. For seven obese cefazolin patients (recorded weight .90 kg) the median dose was 4 g (range 3 -6 g). There were 9/105 (9%) cefazolin patients and 18/249 (7%) cloxacillin patients who received gentamicin as synergistic treatment (P ¼ 0.6648). No patient received rifampicin.
Management
For early intravascular catheter infection, 7/13 (54%) cefazolin patients and 22/34 (65%) cloxacillin patients had their catheter removed (P ¼ 0.5207). For early bone or joint infection, 11/15 (73%) cefazolin patients and 13/28 (46%) cloxacillin patients had bone debridement or joint aspiration (P ¼ 0.1161). For early abscess, 1/2 (50%) cefazolin patients and 12/19 (63%) cloxacillin patients had abscess drainage (P .0.9999).
Mortality
Of 354 patients, 96 (27%) died within 90 days: 21/105 (20%) cefazolin patients and 75/249 (30%) cloxacillin patients. Relative to cloxacillin, cefazolin had an HR for 90 day mortality of 0.62 (95% CI 0.38 -1.00, P ¼ 0.0497) (Figure 2 ).
Significant predictors of 90 day mortality with P.0.2 on univariate analysis (Table S3) are listed in Table 2 . After adjusting for these variables in a multivariable model, cefazolin had an HR for 90 day mortality of 0.60 (95% CI 0.36-1.01, P¼0.0557) ( Table 2) .
Based on propensity scores derived from a multivariable logistic regression, 90 cefazolin patients were matched to 90 cloxacillin patients. After matching, the baseline and SAB clinical characteristics were similar between the two groups ( Table 3 ). The maximum standardized difference of the mean was 0.1240. After matching by propensity score, relative to cloxacillin, cefazolin had an HR for 90 day mortality of 0.58 (95% CI 0.31 -1.08, P ¼ 0.0846) ( Figure S2 ).
Relapse
Of all 354 patients, 10 (3%) had a relapse of S. aureus infection: 6/105 (6%) cefazolin patients and 4/249 (2%) cloxacillin patients. In all relapse cases treated with cefazolin, the infectious focus of the original SAB infection or relapse was a deep-seated infection (Table S4 ). In the groups matched for propensity score, 6/90 (7%) cefazolin patients and 2/90 (2%) cloxacillin patients had a relapse. compared patients who received cefazolin with those who received cloxacillin therapy. Our matched propensity score analysis found no significant statistical difference in 90 day mortality. The upper CI of 1.08 suggests that cefazolin is not inferior to cloxacillin and that there is no clinical difference between the two in terms of mortality.
In our multivariate modelling of mortality, significant predictors of mortality included age, gender, liver cirrhosis and fever. These predictors were also described as significant predictors in previous studies. 19, 20 Based on our study estimates, patients treated with cefazolin were less likely to die within 90 days compared with those treated with cloxacillin, but the CI crossed 1. This is consistent with other studies that compared cefazolin with antistaphylococcal penicillin. 12 -14 There are a few potential explanations for our estimate of cefazolin predicting a lower risk of death than the aforementioned studies. First, the overall mortality rate in our study differed greatly from rates in other studies. The mortality rates reported in the three studies were 49% at 90 days, 12 1% at 90 days 14 and 7.3% at 12 weeks. 13 In contrast, our mortality rate, 27%, seemed to approximate more closely the mortality rate in the management of SAB reported in large US, British and Canadian studies.
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Second, our large sample size group led to a more precise estimate of mortality.
Although not statistically significant, there were more relapse cases in the cefazolin group compared with the cloxacillin group, which was shown in a past study. 14 Our study has several strengths. To our knowledge, it is the largest study comparing cefazolin with antistaphylococcal penicillins. The large sample size and number of events for mortality increased the precision of our estimates. Also, our study included multiple academic and community hospitals, enhancing its generalizability. Moreover, our study estimated mortality and relapses separately, unlike the composite outcomes used in past studies. 13, 14 Lastly, comparison of cloxacillin versus cefazolin in terms of mortality was analysed using a multivariable model and propensity score-matched analysis. The similar estimates from the two methods make our analyses robust.
Our study has limitations that merit mentioning. First, our data came from a retrospective chart review. However, rigorous and systematic data collection followed by regular data verification ensured that the data were of high quality. Second, we anticipated selection bias to be present with respect to assignment of antibiotics. In our study, patients with deep-seated infections, including endocarditis and abscess, were more likely to receive cloxacillin. Physicians may be reluctant to treat severe infections with cefazolin, which may account for higher mortality in cloxacillin patients. To account for this selection bias, we adjusted for baseline patient characteristics, infectious foci and other SAB clinical characteristics in a multivariable model and propensity scorematched analysis. However, our study could not capture all risk factors for fatal outcome, which is impossible in an observational study. Only a randomized controlled trial (RCT) can adequately balance all such prognostic factors. The propensity-matched analysis included only four endocarditis cases, so our results should not be generalized to treatment of S. aureus endocarditis. Third, our definition of predominant antibiotic as .50% of total antibiotic days leaves the possibility of potential crossover of antibiotic treatment, especially in early empirical therapy, which may account for the similarity between the two groups. In our study, crossover in early therapy to cefazolin or cloxacillin was relatively infrequent, at 8% and 14% (Table S5) . Also, early empirical antibiotic therapy might have the most impact on early death, which we excluded in our study. A similar definition of predominant antibiotic therapy has been used in a past study. 21 Lastly, the follow-up was different for in-hospital patients and discharged patients in our study. We cannot exclude the possibility that patients who were lost to follow-up could have died outside the hospital. However, most patients in Toronto who are readmitted after discharge return to the same hospital. 22 Also, the mortality rate in our study was similar if not higher than in other SAB cohorts in long-term follow-up, suggesting that we did not miss a significant number of deaths. 23 -25 Competing risk models analysing only in-hospital death with hospital discharge as a competing event yielded similar results (Table S6) .
Adding to previous studies, our study suggests that cefazolin could be considered along with antistaphylococcal penicillins as first-line treatment for MSSA bacteraemia without any endocarditis or deep-seated infection. A large comparative RCT should be done to confirm our study findings. Until then, it appears that there is no clear difference between the two drugs and clinicians can still choose antibiotic therapy for MSSA based on what is best suited to individual patient characteristics.
